• ZK53: Human Mitochondrial ClpP Workflow

  2026-10-01

  ZK53 is a human mitochondrial serine protease ClpP activator for connecting mitochondrial proteostasis failure with cell-cycle arrest, apoptosis, and ferroptosis sensitivity. This workflow shows how to validate target engagement, separate assay-format effects from biology, and select tumor models for translational experiments.

• Worenine and PBK/SRC Signaling in Pulmonary Fibrosis

  2026-10-01

  A 2026 study combines network pharmacology, molecular docking, cell models, and bleomycin-induced pulmonary fibrosis mice to investigate worenine as a multitarget antifibrotic candidate. Its central contribution is the proposed connection between PBK/SRC-associated signaling and TGF-β1/Smad, ERK, NF-κB, EMT, FMT, collagen deposition, and inflammatory mediator release.

• Tomivosertib and Human DRG Hyperexcitability

  2026-09-30

  The reference study provides direct human-tissue evidence that MNK inhibition with tomivosertib rapidly and reversibly suppresses spontaneous activity in cultured dorsal root ganglion neurons obtained from patients with radiculopathy. Electrophysiological changes and rapid loss of eIF4E Ser209 phosphorylation connect target engagement with reduced neuronal excitability and support further investigation of MNK signaling in neuropathic pain.

• FPS-ZM1 RAGE Inhibitor Workflow for RAGE/POMC

  2026-09-30

  FPS-ZM1 is a selective RAGE inhibitor for separating receptor-driven amyloid beta signaling, neuronal stress, and neuroinflammation from broader metabolic effects. This workflow translates emerging RAGE/POMC findings into practical cell-based, biochemical, and translational assay designs.

• CGP 55845 Hydrochloride and Synaptic Control

  2026-09-29

  A translational framework for using CGP 55845 hydrochloride to separate GABAB receptor signaling from astrocytic GAT-3 control of hippocampal synaptic transmission, with practical assay guidance and clear limits on interpretation.

• Anlotinib VEGFR2 Inhibition: Preclinical Evidence

  2026-09-29

  The reference study established anlotinib as a highly potent and selective VEGFR2 inhibitor that suppresses endothelial signaling, migration, tube formation, and tumor-associated vascular growth. Its integrated biochemical, cellular, ex vivo, and xenograft experiments provide a useful framework for separating anti-angiogenic activity from direct tumor-cell effects.

• CGP 55845 hydrochloride Assay Guide

  2026-09-28

  A scenario-based guide to using CGP 55845 hydrochloride (SKU B5086) in GABAB receptor, neurotransmitter release, and mixed neural-cell assays. It connects receptor pharmacology with practical controls for viability readouts, stock preparation, data interpretation, and vendor selection.

• I-BET-762 for Reliable Viability Assays

  2026-09-28

  Learn how I-BET-762 (SKU B1498) can support BET-inhibition studies in cell viability, ferroptosis, and inflammatory workflows. This scenario-led guide distinguishes published experimental conditions from practical optimization advice and highlights handling, interpretation, and vendor-selection considerations.

• Deep Learning Detects Cardiotoxicity in iPSC-CMs

  2026-09-27

  Grafton et al. combined induced pluripotent stem cell-derived cardiomyocytes with high-content imaging and deep learning to flag compounds with potential cardiotoxic liabilities. Their screen shows how a compact image-based score can help prioritize compounds for follow-up, while underscoring that phenotypic signals require mechanistic and electrophysiological validation.

• Anti Reverse Cap Analog: Workflow & Applications

  2026-09-26

  Improve capped-mRNA expression workflows with orientation-specific ARCA, while keeping transcript design and assay controls aligned with the biological question. This guide connects practical in vitro transcription choices to the TCAIM–OGDH study—and explains where that connection is useful, and where it is only a research extension.

• Intravesical p21 mRNA-LNP for Bladder Cancer

  2026-09-25

  This study develops an intravesical lipid nanoparticle strategy to restore p21 expression in bladder tumors using chemically modified mRNA. Cell and mouse-model findings support local tumor suppression while highlighting the need for further preclinical evaluation of dosing, durability, and safety.

• Magnetic Stimulation Targets GABRE in Schizophrenia Models

  2026-09-25

  In a mouse model, precisely targeting the left prelimbic cortex with combined magnetic stimulation reversed schizophrenia-like behavioral and synaptic abnormalities while reducing GABRE expression. Genetic manipulation of Gabre supports a functional role for this receptor subunit, although the proposed p62/SQSTM1 mechanism and translation to human treatment remain to be established.

• IGFBP2–THBS1 Links GH to IGF-1 Signaling in ISS

  2026-09-24

  A study of idiopathic short stature (ISS) connects growth hormone (GH) treatment to an IGFBP2–THBS1 regulatory axis in chondrocytes, with downstream changes in IGF-1 and markers of cell growth and hypertrophic differentiation. The findings offer a testable mechanism for GH action, while leaving its clinical relevance and contribution to differences in treatment response for future study.

• JHU-083 Workflows for Glutaminase Research

  2026-09-24

  JHU-083 supports glutaminase-pathway studies in cerebral CD11b cells, including experimental cerebral malaria models, with glutamate readouts that help connect target modulation to cell function. This guide pairs a cautious in vitro pilot workflow with redox-assay design lessons from α-amanitin hepatotoxicity research—while clearly separating that study’s findings from evidence about JHU-083.

• NSD1–PPARγ Methylation Restrains EC Glycolysis

  2026-09-23

  The study identifies a non-histone role for NSD1: methylation of PPARγ at K98 promotes nuclear localization and PTEN expression, linking epigenetic regulation to glycolytic restraint in endometrial cancer. Rescue experiments indicate that restoring PTEN or inhibiting AKT can counter features associated with NSD1 loss, although the available report does not establish clinical efficacy or provide enough protocol detail to reproduce exact experimental conditions.

8557 records 1/571 page Next 12345 下5页 Last page